Print
Email
Print Edition Stories
Funding drugs for rare diseases
Cambridge biopharmaceutical Acceleron Pharma Inc. has raised $8.4 million of a planned $11.5 million securities offering, according to a regulatory filing with the U.S. Securities and Exchange Commission.
The company develops novel therapeutics that modulate the growth of cells and tissues, including muscle, bone, fat, red blood cells and the vasculature.
Accleron’s investors as listed on its website include Advanced Technology Ventures, Bessemer Venture Partners, Flagship Ventures, MPM Capital, OrbiMed Advisers, Polaris Venture Partners, Sutter Hill Ventures and Venrock Associates.
Acceleron was co-founded in 2004 by former Mass High Tech All-Star Cristoph Westphal, head of GlaxoSmithKline PLC’s Centre of Excellence for External Drug Discovery.
The company raised $11 million in equity financing in December. The financing was preceded by a $31 million Series C round in 2007.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
